Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: Atropine Sulphate Injection BP 600 micrograms/1ml (2012)

Εκδότης

Εκδότης Mercury Pharma Group
Διεύθυνση No. 1 Croydon, 12 - 16 Addiscombe Road, Croydon, Surrey, CR0 0XT, UK
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

Atropine Sulphate 600 micrograms/ml Solution for Injection

Qualitative and quantitative composition

Each 1ml of solution contains 600 micrograms of Atropine Sulphate B.P.

Pharmaceutical form

Clear, colourless, sterile, aqueous solution intended for parenteral administration to human beings. ...

Therapeutic indications

In anaesthesia, to reduce the risk of vagal inhibition of the heart and to reduce salivary and bronchial ...

Posology and method of administration

1. Use in Anaesthesia Adults (including the elderly): The usual dose is 0.3 to 0.6mg (300 micrograms ...

Contraindications

Known hypersensitivity to atropine and in myasthenia gravis (except when given with an anticholinesterase). ...

Special warnings and precautions for use

Atropine sulphate should be used with caution in children, the elderly and those with Downs syndrome ...

Interaction with other medicinal products and other forms of interaction

Drugs with anticholinergic effects including antihistamines, tricyclic antidepressants, monoamine oxidase ...

Pregnancy and lactation

Pregnancy Atropine sulphate crosses the placenta. Studies in humans have not been done and only limited ...

Effects on ability to drive and use machines

Not applicable, as the patient would be too ill.

Undesirable effects

Side effects include dry mouth, dysphagia, dry skin, thirst, dilated pupils with loss of accommodation ...

Overdose

Symptoms Marked dryness of the mouth accompanied by a burning sensation, difficulty in swallowing, pronounced ...

Pharmacodynamic properties

Atropine is an antimuscarinic agent which competitively antagonizes acetylcholine at postganglionic nerve ...

Pharmacokinetic properties

Following intravenous administration, the peak increase in heart rate occurs within 2 to 4 minutes. Peak ...

Preclinical safety data

Not applicable since atropine has been used in clinical practice for many years and its effects in man ...

List of excipients

Dilute Sulphuric Acid BP Water for Injections BP (in bulk)

Incompatibilities

Atropine Sulphate Injection is incompatible with alkalis, tannic acid and mercury salts.

Ημερομηνία λήξης

Unopened: 4 years* After reconstitution: not applicable. * If only part of an ampoule is used, the remainder ...

Special precautions for storage

Store below 25°C. Protect from light.

Nature and contents of container

1ml, clear One point cut (OPC) glass ampoules, glass Type I Ph. Eur. Borosilicate glass packed in cardboard ...

Special precautions for disposal and other handling

For S.C., I.M. or I.V. injection. Use as directed by the physician. Keep out of reach of children. If ...

Marketing authorization holder

Mercury Pharma International Ltd. 4045, Kingswood Road City West Business Park Co Dublin Ireland

Marketing authorization number(s)

PL 02848/5912R

Date of first authorization / renewal of the authorization

26/2/91

Date of revision of the text

13.06.2012
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.